Provided by Tiger Trade Technology Pte. Ltd.

LeonaBio Inc

3.57
+0.06001.71%
Pre-market: 3.48-0.0900-2.52%06:31 EDT
Volume:40.26K
Turnover:139.79K
Market Cap:33.53M
PE:-0.16
High:3.59
Open:3.51
Low:3.31
Close:3.51
52wk High:14.21
52wk Low:2.21
Shares:9.39M
Float Shares:4.73M
Volume Ratio:0.11
T/O Rate:0.85%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-23.0100
EPS(LYR):-24.7000
ROE:-431.39%
ROA:-74.07%
PB:1.00
PE(LYR):-0.14

Loading ...

LeonaBio Says Share Purchase Warrants Become Exercisable at USD 6.35 Per Share

Reuters
·
Sep 23

Analysts’ Top Healthcare Picks: LeonaBio (LONA), Immunovant (IMVT)

TIPRANKS
·
Sep 21

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Sep 15

LeonaBio Files Initial Beneficial Ownership Statement for David J. Portman

Reuters
·
Sep 04

LeonaBio Management Joins Cantor Global Healthcare Conference Fireside Chat

Reuters
·
Sep 03

Leonabio - Enrolls 500TH Subject in Phase 3 Elaine-3 Trial for Lasofoxifene with Abemaciclib - SEC Filing

THOMSON REUTERS
·
Aug 27

LeonaBio Warrants Become Exercisable at $6.35 a Share, Could Raise About $146.2 Million

Reuters
·
Aug 27

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Aug 17

LeonaBio Narrows Q2 Loss

MT Newswires Live
·
Aug 15

LeonaBio Q2 EPS $(0.80) Beats $(1.36) Estimate

Benzinga Earnings
·
Aug 15

LeonaBio Q2 FY26 Net Loss Widens to $19 Million; R&D Expenses More than Doubled to $12.9 Million

Reuters
·
Aug 15

LeonaBio, Inc Q2 EPS USD -0.8

Reuters
·
Aug 15

Press Release: LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
Aug 15

LeonaBio Targets Phase 3 Elaine-3 Enrollment Completion in Q4 2026, Topline Data Seen in H2 2027

Reuters
·
Aug 12

LeonaBio Spotlights Lasofoxifene at DAVA Oncology Breast Cancer Summit

Reuters
·
Aug 12

LeonaBio Inc Expected to Post a Loss of $1.26 a Share - Earnings Preview

Reuters
·
Aug 03

LeonaBio Raised to Market Outperform from Market Perform by Citizens

Dow Jones
·
Jul 30

LeonaBio upgraded to Outperform from Market Perform at Citizens

TIPRANKS
·
Jul 30

LeonaBio stockholders back Ernst & Young as 2026 auditor at annual meeting

Reuters
·
Jun 24

LeonaBio Presents on ATH-1105 at 5th Annual ALS Drug Development Summit

GlobeNewswire
·
Jun 04